Hormonal
GLP-1 receptor agonists (specifically liraglutide, semaglutide, and dulaglutide) significantly reduce major adverse cardiovascular events (MACE) in patients with type 2 diabetes and high cardiovascular risk, independent of baseline BMI.
If you have Type 2 Diabetes and high heart risk, GLP-1 medications like liraglutide, semaglutide, or dulaglutide are proven to significantly lower your risk of heart attack, stroke, and heart-related death. These benefits exist even if your weight loss isn't massive. Discuss these options with your doctor, especially if you have existing heart disease.
There was a 13% reduction in the primary composite outcome (death from CV causes, non-fatal myocardial infarction, or non-fatal stroke) in the liraglutide group compared to placebo (HR 0.87, 95% CI 0.78 – 0.97, p<0.001)... There was a 26% reduction in the primary outcome... in the semaglutide group compared to placebo (HR 0.74, 95% CI 0.58 – 0.95, p <0.001)... there was a 12% reduction in the primary outcome in the dulaglutide group compared to the placebo (HR 0.88, 95% CI 0.79 – 0.99, p¼0.026).
Why this rating
Based on multiple large-scale, long-duration Randomized Controlled Trials (RCTs) with clear statistical significance.
Source
A review of the evidence on cardiovascular outcomes from obesity treatment
Roshaida Abdul Wahab et al. · Obesity Pillars · 2023
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →